Viking Therapeutics stock has already tripled in 2024, but Wall Street analysts think it has more room to run. Viking Therapeutics' lead candidate is an experimental weight management treatment that ...
Pre-earnings options volume in Viking Therapeutics (VKTX) is normal with calls leading puts 9:4. Implied volatility suggests the market is ...
Zacks Investment Research on MSN
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest close session, Viking Therapeutics, Inc. (VKTX) was down 2.54% at $33.05. This move lagged the S&P 500's daily loss of 0.16%. Meanwhile, the Dow experienced a rise of 0.44%, and the ...
Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage drugmaker working on metabolic treatments, have tripled in value this year. Despite the huge run-up, analysts who follow the company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback